We then evaluated the relationship between the plasma stages in our model and key AD markers, including insoluble Aβ aggregates (Aβ-PET), insoluble tau aggregates (tau-PET) at mediotemporal (MTL) and temporal neocortex (NeoT) regions, neurodegeneration (cortical thickness) and cognitive performance. The gene discussed is MAPT; the disease is Alzheimer disease.